Compare Stocks → Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BPMUFNASDAQ:CRBPNASDAQ:FLXNNASDAQ:OVASNASDAQ:THOR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$44.45$40.99$38.60▼$44.45$526.73M0.655 shsN/ACRBPCorbus Pharmaceuticals$37.16-9.6%$34.37$3.03▼$49.87$390.55M2.46824,649 shs419,840 shsFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/AOVASOvaScience$3.27-2.4%$12.74$0.66▼$1.52$117.16M3.11163,131 shs345,303 shsTHORSynthorx$67.99$67.99$11.05▼$71.90$2.20BN/A474,507 shsN/A20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%+9.08%+9.08%+8.41%-14.52%CRBPCorbus Pharmaceuticals-3.75%+9.74%-5.86%+568.62%+293.12%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%OVASOvaScience-6.69%-13.44%-7.97%-21.08%-9.46%THORSynthorx0.00%0.00%0.00%0.00%0.00%Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/ACRBPCorbus Pharmaceuticals4.3848 of 5 stars3.53.00.04.72.63.30.6FLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea PharmaceuticaN/AN/AN/AN/ACRBPCorbus Pharmaceuticals3.00Buy$52.0039.94% UpsideFLXNFlexion TherapeuticsN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/ACurrent Analyst RatingsLatest CRBP, OVAS, FLXN, BPMUF, and THOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.001/29/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $51.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$175.50M3.00$1.13 per share39.34($0.94) per share-47.29CRBPCorbus Pharmaceuticals$880K443.81N/AN/A($1.56) per share-23.82FLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82OVASOvaScience$290K404.01N/AN/A$1.80 per share1.82THORSynthorxN/AN/AN/AN/A$6.72 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$11.64MN/A0.0014.92N/AN/AN/AN/AN/ACRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)FLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AOVASOvaScience-$50.97MN/A0.00∞N/A-10,128.37%-47.06%-42.39%N/ATHORSynthorx-$56.61M-$6.59N/AN/AN/AN/A-26.09%-24.62%N/ALatest CRBP, OVAS, FLXN, BPMUF, and THOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea PharmaceuticaN/A3.202.64CRBPCorbus PharmaceuticalsN/A0.740.74FLXNFlexion TherapeuticsN/A4.384.05OVASOvaScienceN/A12.6212.62THORSynthorxN/A18.8718.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/ACRBPCorbus Pharmaceuticals64.64%FLXNFlexion Therapeutics90.01%OVASOvaScience22.52%THORSynthorx66.12%Insider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/ACRBPCorbus Pharmaceuticals4.00%FLXNFlexion Therapeutics9.13%OVASOvaScience7.40%THORSynthorx53.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14711.85 millionN/ANot OptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableOVASOvaScienceN/A35.83 millionN/ANot OptionableTHORSynthorx4832.34 millionN/ANot OptionableCRBP, OVAS, FLXN, BPMUF, and THOR HeadlinesSourceHeadlineDesign Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 21 at 4:55 PMDesign Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 20 at 3:52 PMEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officerfinance.yahoo.com - March 14 at 10:35 AMDupixent Redux? Synthekine, Sanofi Partner on Cytokine Therapiesgenengnews.com - January 29 at 6:12 PMSanofi pays Synthekine $40M to join preclinical push against vexing inflammatory targetfiercebiotech.com - January 29 at 8:12 AMEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directorsfinance.yahoo.com - December 19 at 10:44 AM‘We Have a Whole Ecosystem’: Barbara Borden Reflects on Blockbuster Horizon-Amgen Deal and Life Sciences Deals to Comelaw.com - November 2 at 3:05 PMPegenzileukin by Sanofi for Non-Small Cell Lung Cancer: Likelihood of Approvalpharmaceutical-technology.com - October 27 at 7:17 PMPegenzileukin by Sanofi for Squamous Cell Carcinoma: Likelihood of Approvalpharmaceutical-technology.com - June 10 at 10:29 AMPegenzileukin by Sanofi for Diffuse Large B-Cell Lymphoma: Likelihood of Approvalpharmaceutical-technology.com - June 10 at 10:29 AMMerck's $11B Prometheus Acquisition Brings IBD Drug & Precision ... - MedCity Newsnews.google.com - April 17 at 8:37 PMCapstan Therapeutics Appoints Justin Thacker as Chief Financial ... - Business Wirenews.google.com - March 22 at 5:01 PMCapstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel - Yahoo Financenews.google.com - March 22 at 12:00 PMSanofi Goes All In For Type 1 Diabetes With Provention Buy - Scripnews.google.com - March 13 at 9:01 PMPegenzileukin by Sanofi for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approvalpharmaceutical-technology.com - March 3 at 10:18 PMBridge holds firm despite placebo beating drug in midphase ... - FierceBiotechnews.google.com - February 21 at 11:20 AMBiosimilar Interleukins Global Market Report 2023uk.finance.yahoo.com - February 16 at 10:03 AMReed Reaches End Of The Road As Sanofi R&D Chief - Scripnews.google.com - February 13 at 6:15 PM'Robust Ecosystem' Gives Strength to San Diego's Life Science Sector - San Diego Business Journalnews.google.com - February 6 at 4:43 PMGlobal Glucagon-like Peptide 1 (GLP-1) Market Research Report ... - WV Newsnews.google.com - January 30 at 9:54 AMBiosimilar Interleukins Market Size, Share And Growth Analysis For 2023-2032 - EIN Newsnews.google.com - January 19 at 1:28 PMGlobal Glucagon-like Peptide 1 Market: Analysis By Product, By Route of Administration, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027 - Yahoo Financenews.google.com - January 19 at 8:27 AMPD-1 and PDL-1 Inhibitors Market is forecast to reach a value of US ... - Medgadgetnews.google.com - January 19 at 8:27 AMResearchers, Industry Experts Discuss “The Future of mRNA ... - BioBuzznews.google.com - January 16 at 1:58 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBasilea PharmaceuticaOTCMKTS:BPMUFBasilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Corbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.OvaScienceNASDAQ:OVASMillendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI.SynthorxNASDAQ:THORSynthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.